Skip to main content
OpenTrials

Clinical trial condition

Recurrent Lung Non-Small Cell Carcinoma

Explore clinical trials studying Recurrent Lung Non-Small Cell Carcinoma. Study availability and eligibility vary by location and protocol.

46 public trials 11 recruiting studies
Refine in advanced search Browse all conditions

Recurrent Lung Non-Small Cell Carcinoma trial results

Active, Not Recruiting

Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

NCT01708954

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Memorial Medical Center Modesto, California, United States
  • Community Hospital of Monterey Peninsula Monterey, California, United States
  • Stanford Cancer Institute Palo Alto Palo Alto, California, United States
View all 356 locations
View Trial Details
Active, Not Recruiting

Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

NCT04227028

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +17 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • University of Colorado Cancer Center Aurora, Colorado, United States
  • Northwestern University Chicago, Illinois, United States
  • Rush University Medical Center Chicago, Illinois, United States
View Trial Details
Active, Not Recruiting

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

NCT02503722

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +13 more
Locations
  • Smilow Cancer Center/Yale-New Haven Hospital New Haven, Connecticut, United States
  • Yale University New Haven, Connecticut, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • BCCA-Vancouver Cancer Centre Vancouver, British Columbia, Canada
View Trial Details
Active, Not Recruiting

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

NCT04514484

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Differentiated Thyroid Gland Carcinoma, +141 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • Montefiore Medical Center-Einstein Campus The Bronx, New York, United States
  • University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States
View Trial Details
Active, Not Recruiting

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

NCT04250545

Conditions
Brain Diseases, Brain Neoplasms, Bronchial Neoplasms, +21 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • City of Hope at Irvine Lennar Irvine, California, United States
  • Keck Medicine of USC Koreatown Los Angeles, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
View Trial Details
Active, Not Recruiting

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

NCT05096663

Conditions
Advanced Lung Non-Small Cell Carcinoma, Bronchial Neoplasms, Carcinoma, Bronchogenic, +16 more
Locations
  • Veterans Administration Medical Center - Birmingham Birmingham, Alabama, United States
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Kaiser Permanente-Anaheim Anaheim, California, United States
View all 350 locations
View Trial Details
Active, Not Recruiting

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

NCT05633602

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
View all 566 locations
View Trial Details
Active, Not Recruiting

Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

NCT03410043

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +13 more
Locations
  • UCSF Medical Center-Mount Zion San Francisco, California, United States
  • University of Colorado Denver, Colorado, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • M D Anderson Cancer Center Houston, Texas, United States
View Trial Details
Active, Not Recruiting

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

NCT04268550

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +11 more
Locations
  • Fairbanks Memorial Hospital Fairbanks, Alaska, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Kaiser Permanente-Anaheim Anaheim, California, United States
  • Sutter Auburn Faith Hospital Auburn, California, United States
View all 306 locations
View Trial Details

Related conditions